The Latest in Leukemia, Myelodysplasia, Transplantation

Eltrombopag ‘cannot be recommended’ during AML induction

February 9, 2019

Leukemia, Myelodysplasia, Transplantation

PD-1 blockade plus CD19 CAR T boosts CAR T-cell persistence

February 8, 2019

Immunotherapy’s cardiac effects require early monitoring, management

February 5, 2019

FDA approves ibrutinib plus obinutuzumab for CLL/SLL

January 28, 2019

Leukemia, Myelodysplasia, Transplantation

EC approves blinatumomab for MRD-positive BCP-ALL

January 25, 2019

Leukemia, Myelodysplasia, Transplantation

Uninterrupted ibrutinib with CAR T could improve CLL outcomes

January 25, 2019

AML, myeloma risk higher for breast cancer survivors

January 22, 2019

FDA approves new ALL treatment for children, young adults

January 7, 2019

Leukemia, Myelodysplasia, Transplantation

ALL chemotherapy looks effective in mixed phenotype leukemia

January 3, 2019

Higher AML, MDS risk linked to solid tumor chemotherapy

January 3, 2019

FDA expands dasatinib indication to children with Ph+ ALL

January 3, 2019

Leukemia, Myelodysplasia, Transplantation

Quizartinib improves survival of FLT3-mutated AML

January 2, 2019

Leukemia, Myelodysplasia, Transplantation

FDA approves Elzonris for blastic plasmacytoid dendritic cell neoplasm

December 21, 2018

Ibrutinib-rituximab ‘new standard of care’ in younger CLL patients

December 11, 2018

Leukemia, Myelodysplasia, Transplantation

CLL resistance mechanism to venetoclax identified

December 5, 2018